序号股票简称PE(TTM)PE(静)市净率总市值(元)13东星医疗28.9926.661.1525.97亿行业平均 51.4249.164.50106.60亿行业中值37.4437.842.5151.15亿1九安医疗10.2110.330.80172.35亿2英科医疗 10.4111.230.93164.55亿3新华医疗14.3013.251.1791.67亿4奥美医疗15.3415.031.5855.41亿5振德医疗 15.3614.470.9855.74亿6山东药玻15.4115.461.77145.80亿7康德莱15.7915.801.3134.03亿8九强生物 16.5115.352.0281.78亿9维力医疗16.5717.221.9437.78亿10奥泰生物16.5817.491.3452.89亿11安杰思 17.4517.662.1151.81亿12普门科技18.9816.042.6355.40亿 江苏东星智慧医疗科技股份有限公司的主营业务是外科手术医疗器械的研发、生产和销售。公司的主要 产品是腔镜吻合器、开放式吻合器、吻合器零部件、电动液压手术床、手术无影灯、吊塔吊桥、产床。 最新一期业绩显示 ...

7月3日，东星医疗今日收盘25.43元，上涨4.22%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到28.43倍，创13天以来新低，总市值25.47亿元。 江苏东星智慧医疗科技股份有限公司的主营业务是外科手术医疗器械的研发、生产和销售。公司的主要 产品是腔镜吻合器、开放式吻合器、吻合器零部件、电动液压手术床、手术无影灯、吊塔吊桥、产床。 最新一期业绩显示，2025年一季报，公司实现营业收入7818.65万元，同比-14.84%；净利润1206.40万 元，同比-39.35%，销售毛利率44.40%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13东星医疗28.4326.151.1325.47亿行业平均 51.4848.994.51106.54亿行业中值36.8836.802.4850.74亿1九安医疗10.2910.400.81173.59亿2英科医疗 10.4311.240.93164.74亿3新华医疗14.5213.461.1893.06亿4奥美医疗15.4115.101.5855.66亿5山东药玻 15.4515.501.78146.13亿6振德医疗15.5914.690.9 ...

Group 1 - The core viewpoint of the articles indicates that Dongxing Medical's stock is currently underperforming compared to its industry peers, with a PE ratio of 27.35, significantly lower than the industry average of 49.45 [1][2] - Dongxing Medical's market capitalization stands at 2.45 billion yuan, ranking 62nd in the medical device industry based on PE ratio [1][2] - The company reported a revenue of 78.19 million yuan for Q1 2025, reflecting a year-on-year decline of 14.84%, and a net profit of 12.06 million yuan, down 39.35% year-on-year, with a gross margin of 44.40% [1] Group 2 - The medical device industry has an average PE ratio of 49.45 and a median of 35.92, indicating a generally higher valuation compared to Dongxing Medical [2] - The main products of Dongxing Medical include surgical instruments such as endoscopic staplers, open staplers, and electric hydraulic surgical beds [1] - In terms of capital flow, Dongxing Medical experienced a net outflow of 851,900 yuan on June 26, but had a total inflow of 4.25 million yuan over the past five days [1]

Core Viewpoint - The company has decided to terminate part of its fundraising projects and delay others, based on a careful assessment of the current market conditions and project progress, ensuring that these decisions align with the long-term interests of the company and its shareholders [1][10]. Fundraising Overview - The company raised a net amount of RMB 1,002,572,682.71 through its initial public offering, verified by an accounting firm [1]. - The company has established a management system for the use of raised funds, ensuring that funds are stored in dedicated accounts and used strictly for their intended purposes [2]. Termination of Fundraising Projects - The project "Zihang Medical Device Component Intelligent Manufacturing and Expansion Project" will be terminated, with the total investment amount reduced from RMB 282.84 million to RMB 143.47 million, and the fundraising investment amount decreased from RMB 282.84 million to RMB 135.77 million [3]. - The termination is influenced by changes in market demand and increased competition, leading to a reassessment of the project's viability [6][7]. Reasons for Project Termination - The implementation of centralized procurement policies has created volatility in market demand, affecting the sales cycle and capacity planning for the project [6]. - The existing production capacity is deemed sufficient to meet current demand, and further investment could lead to idle capacity risks [7]. Impact of Project Termination - The termination is expected to enhance the efficiency of fundraising usage and will not adversely affect the company's normal operations or shareholder interests [8]. - The remaining funds from the terminated project will be retained in dedicated accounts for future investment opportunities [8]. Delay of Fundraising Projects - The "Weike Medical Minimally Invasive Surgical New Product Project" will be delayed, with the expected completion date pushed from June 30, 2025, to December 31, 2027 [9]. - The delay is attributed to changes in market conditions and the need for further product development to meet diverse customer needs [9]. Reasons for Project Delay - The company is adapting to market changes and enhancing product features through increased R&D investment, which has necessitated a phased approach to project implementation [9]. - The execution of procurement policies has affected the expected market release timeline for the company's products [9]. Impact of Project Delay - The delay is a strategic decision that does not involve changes to the project’s implementation structure or total investment, ensuring that it aligns with the company's long-term development goals [9][10].

5月20日，东星医疗今日收盘24.09元，上涨1.52%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到26.93倍，总市值24.13亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入7818.65万元，同比-14.84%；净利润1206.40万 元，同比-39.35%，销售毛利率44.40%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)58东星医疗26.9324.771.0724.13亿行业平均 49.5147.734.57106.36亿行业中值36.1737.202.5148.58亿1天益医疗-1784.15-3056.061.9022.74亿2澳华内 镜-619.74310.834.9665.31亿3诺唯赞-415.76-491.732.2888.97亿4爱朋医疗-370.37281.374.4630.39亿5博晖 创新-330.72524.813.5348.52亿6硕世生物-137.27-2005.841.2340.15亿7奥精医疗-130.15-190.761.7224.15亿 8睿昂基因-105.86-86.911.5013.70亿9康泰医学-86.99-73. ...

江苏东星智慧医疗科技股份有限公司的主营业务是外科手术医疗器械的研发、生产和销售。公司的主要 产品是腔镜吻合器、开放式吻合器、吻合器零部件、电动液压手术床、手术无影灯、吊塔吊桥、产床。 最新一期业绩显示，2025年一季报，公司实现营业收入7818.65万元，同比-14.84%；净利润1206.40万 元，同比-39.35%，销售毛利率44.40%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)61东星医疗27.3825.181.0924.53亿行业平均 49.8447.964.65106.43亿行业中值36.6538.442.4547.58亿1天益医疗-1720.32-2946.711.8421.92亿2澳华内 镜-589.71295.774.7262.15亿3诺唯赞-415.01-490.852.2888.81亿4爱朋医疗-368.22279.744.4430.21亿5博晖 创新-326.27517.743.4847.87亿6硕世生物-135.93-1986.301.2239.76亿7奥精医疗-120.78-177.021.5922.41亿 8睿昂基因-97.79-80.291.3912.66亿9康 ...

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 2025年4月14日， 东星医疗 发布了2024年年报。 #财报数据 东星医疗2024年年报显示， 公司营业总收入为 4.35亿元 ，同比增长 0.40% ；归属于上市公司股东的净利 润为9742.48万元，同比增长0.21%。 # 关于东星医疗 东星医疗成立于2001年2月，是一家集科、工、贸为一体的平台化企业， 主要从事以吻合器为代表的外科手术医疗器械的研发、生产和销售。 公司于2022年11月30日在深交所创业板上市。公司产品涵盖吻合器、手术室灯塔床等外科高值耗材及 营业收入： 43,546.31万元，同比增长0.40%。其中，医疗器械行业收入 33,373.78万元 ，占比 76.64% ，较上年增长1.61%；其他行业收入10,172.52万元，占比23.36%，较上年下降3.37%。 净利润：9689.12万元 ，同比下降 2.99% ；扣非归母净利润为6645.91万元，同比下降2.49%。 现金流量： 经营活动现金净流入为 1.26亿元 ...